Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Melphalan
Drug ID BADD_D01376
Description An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen.
Indications and Usage For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
Marketing Status Prescription; Discontinued
ATC Code L01AA03
DrugBank ID DB01042
KEGG ID D00369
MeSH ID D008558
PubChem ID 460612
TTD Drug ID D00FGO
NDC Product Code 68152-109; 71052-158; 52609-0001; 68554-0076; 50683-0385; 72893-001; 43744-361; 76055-0021; 72969-046
Synonyms Melphalan | L-PAM | Phenylalanine Mustard | Mustard, Phenylalanine | 4-(Bis(2-chloroethyl)amino)phenylalanine | Medphalan | Sarkolysin | Sarcolysine | Merphalan | Alkeran
Chemical Information
Molecular Formula C13H18Cl2N2O2
CAS Registry Number 148-82-3
SMILES C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chromosomal abnormalities and abnormal gene carriersTribbles homolog 3Q96RU7Not Available11359799; 12649745; 10843675
InjuryT-lymphocyte activation antigen CD80P33681T5823811359799; 12649745; 10843675
InjuryElongator complex protein 1O95163T4988811359799; 12649745; 10843675
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood alkaline phosphatase increased13.04.02.0040.006660%
Retinogram abnormal13.07.05.0010.003197%Not Available
Connective tissue disorder15.06.01.006--Not Available
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Blood disorder01.05.01.004--Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.013--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Venoocclusive disease24.03.02.016--Not Available
Renal impairment20.01.03.0100.000533%Not Available
Cystitis noninfective20.03.02.001--
Idiopathic pneumonia syndrome22.01.02.015; 12.02.07.0060.000208%Not Available
Bone marrow failure01.03.03.005--
Cytopenia01.03.03.0120.000533%Not Available
Acute kidney injury20.01.03.016--
Posterior reversible encephalopathy syndrome17.13.02.0070.000533%
Slow speech19.19.02.004; 17.02.08.0160.000533%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000139%
Acute myelomonocytic leukaemia16.01.05.005; 01.10.05.0050.000208%Not Available
Chorioretinal atrophy06.09.01.0100.002664%Not Available
Neuralgic amyotrophy10.04.10.014; 17.09.03.018; 15.05.05.0170.000533%Not Available
Retinal pigment epitheliopathy06.09.03.0240.001865%Not Available
Primary hypogonadism21.03.02.025; 05.05.04.0090.000533%Not Available
Growth hormone deficiency05.03.02.0040.000533%Not Available
Atrophy of globe06.09.04.0070.002131%Not Available
The 6th Page    First    Pre   6    Total 6 Pages